glp 1 pregnancy risk Periconceptional GLP-1 receptor agonist exposure and obstetric outcomes: a Danish nationwide cohort study RACGP - Unplanned pregnancy risks

Clinical trial data

Derhovanessian E, Maier AB, Beck R, Jahn G, Hahnel K, Slagboom PE, et al

Research peptides in this space fall into two distinct mechanistic categories: GHRH analogs (e.g., CJC-1295, Sermorelin, Tesamorelin ) bind the GHRH receptor on pituitary somatotrophs to directly stimulate GH synthesis and release GHRPs / Ghrelin mimetics (e.g., Ipamorelin, GHRP-2, GHRP-6, Hexarelin) bind the GHS-R1a receptor to amplify GH release through a separate, complementary pathway Ipamorelin falls firmly in the GHRP/ghrelin mimetic category

Similar content being viewed by others Background Glucagon-like peptide 1 receptor agonists (GLP-1RAs) are modified derivatives of glucagon-like peptide 1 (GLP-1) that simulate the regulatory effect of GLP-1 on blood glucose levels